US 9,388,221

Application 13/772,893 · Granted Jul 12, 2016

Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies

Estimated expiration

February 1, 2026

Expired 294 days ago

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Feb 1, 2006
+ 20 years
Feb 1, 2026
PTA +0d
Feb 1, 2026
TD applied
Feb 1, 2026
Final
Feb 1, 2026

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
February 21, 2013
Earliest effective filing
February 1, 2006
Issue date
July 12, 2016
PTA
0 days
Base expiry (before PTA)
February 1, 2026

February 1, 2006 + 20 years = February 1, 2026

  • Continuation of application 11/883,495, filed May 13, 2008, issued as US 8,404,244
  • National stage entry of application PCTUS2006003601, filed Feb 1, 2006
  • National stage entry of application PCTUS2006003601, filed Feb 1, 2006
  • PRO60/649,249 — Provisional — not used for base term
  • PRO60/697,655 — Provisional — not used for base term
  • PRO60/752,268 — Provisional — not used for base term
  • PRO60/649,249 — Provisional — not used for base term
  • PRO60/697,655 — Provisional — not used for base term
  • PRO60/752,268 — Provisional — not used for base term
  • PRO60/649,249 — Provisional — not used for base term
  • PRO60/697,655 — Provisional — not used for base term
  • PRO60/752,268 — Provisional — not used for base term

Terminal disclaimers

TD approved3 approved, 3 filed

TD caps expiration to February 1, 2026

  • US 8,404,244· Application 11/883,495Capping patent

    Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies

    Filing date
    May 13, 2008
    Earliest effective filing
    Feb 1, 2006
    Issue date
    Mar 26, 2013
    PTA
    +1191 days
    Calculated expiration
    May 7, 2029

    National stage entry of PCTUS2006003601, filed Feb 1, 2006

    Feb 1, 2006 + 20y + 1191d PTA = May 7, 2029

  • US 9,388,221· Application 13/772,893(from application 13/772,893)Capping patent

    Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies

    Filing date
    Feb 21, 2013
    Earliest effective filing
    Feb 1, 2006
    Issue date
    Jul 12, 2016
    PTA
    0 days
    Calculated expiration
    Feb 1, 2026

    Continuation of 11/883,495, filed May 13, 2008, issued as US 8,404,244

    National stage entry of PCTUS2006003601, filed Feb 1, 2006

    National stage entry of PCTUS2006003601, filed Feb 1, 2006

    Feb 1, 2006 + 20y = Feb 1, 2026

  • US 10,981,127· Application 15/564,092(from application 15/564,092)

    Mixing group and method for mixing two compounds

    Filing date
    Oct 3, 2017
    Earliest effective filing
    Apr 15, 2016
    Issue date
    Apr 20, 2021
    PTA
    +462 days
    Calculated expiration
    Jul 21, 2037

    National stage entry of PCTIB2016052151, filed Apr 15, 2016

    Apr 15, 2016 + 20y + 462d PTA = Jul 21, 2037

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/772,893 · US 9,388,221

PatentReply compiles the prosecution history behind US 9,388,221: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9388221

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.